2024年12月30日 · Mechanistically, CCT-217 achieved 42-fold silencing of CB1R and 14.5-fold silencing of ZFP423 specifically in iWAT, with no off-target effects observed in liver or brain. In conclusion, CCT-217 emerges as a landmark therapy that effectively reduces visceral fat, enhances lean mass composition, and restores metabolic health through precise ...

At Canary Cure, Dr. Reddy oversees the preclinical pipeline of promising gene and RNA therapies, driving their development with a personalized, AI-enhanced approach. He has led the development of a novel gene therapy candidate for a rare brain disease and has multiple patents related to genetic mechanisms, RNA therapeutics, and vector design.

2024年8月19日 · Canary Cure has a robust pipeline of patented gene and RNA therapies in obesity and neurological diseases and is currently raising $110 million to complete a Series A round to advance CCT-217 through clinical trials and towards commercialization.

2024年12月30日 · lean mass loss, CCT-217 preserves and improves lean body composition while significantly reducing visceral adiposity (Karakasis et al.). Its targeted action minimizes CNS and liver-related off-target effects, addressing limitations of traditional CB1R inverse agonists. CCT-217 represents a transformative advancement in obesity therapy.

2025年1月15日 · Canary Cure的CCT-217 (siRNA，沉默大麻素 CB1 受体（CB1R）和锌指蛋白 423（ZFP423）),临床前小鼠研究，20 天内，通过选择性减少脂肪量，实现了 26%-34% 的总体重减轻；与对照组相比，显著保留了瘦体重成分并增加了 25%，计划在 2025Q3提交IND. A股开户 ｜ 雪球基金 ｜ 投资者教育 ｜ 风险提示.

2024年11月18日 · Canary Cure's CCT-217 therapy targets the CB1r gene, which is part of the endocannabinoid system (ECS). The ECS influences energy balance, fat storage, and food intake. By targeting CB1r gene...

2024年8月19日 · Canary Cure has a robust pipeline of gene and RNA therapies in obesity and neurological diseases and is currently raising $110 million to complete a Series A round to advance CCT-217 through ...

Canary Cure's CCT-217 therapy targets the CB1r gene, which is part of the endocannabinoid system (ECS). The ECS influences energy balance, fat storage, and food intake. By targeting CB1r gene with siRNA, CCT-217 aims to promote weight loss and improve metabolic health.

2024年12月30日 · Here, we present CCT-217, a groundbreaking siRNA therapy targeting CB1R and ZFP423 genes, with strong adipose tissue-specific tropism with nil brain and liver penetration in diet-induced obese (DIO) C57BL/6J male mice model (n=7 control, n=5 treated).

2025年1月10日 · Canary Cure Therapeutics is at the forefront of an exciting development in obesity treatment with its innovative siRNA therapeutic known as CCT-217. This promising candidate has demonstrated significant fat loss and remarkable preservation of lean body mass in preliminary studies.